Pay in 4 interest-free payments of $5.77 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Pathogenesis and Prevention of Hepatic Steatosis
In January 2025, Metsera, a New York-based obesity healthcare company, announced positive topline results from its Phase IIa clinical trial for MET-097i, a glucagon-like peptide-1 receptor agonist (GLP-1RA)
Transparente regler, let adgang til support og en loyalitetsstruktur, der faktisk belnner aktivitet, betyder meget
In order to qualify for the study patients had to be at least 18 years of age with a diagnosis of type 2 diabetes and treated for at least three months with diet and exercise and/or a stable regiment of metformin, as well as an HbA1c level of 7-10% and a body weight of 60-110 kg
US$ 27.97
.png?sfvrsn=1e7191c0_3)
US$ 23.40
US$ 25.99
